摘要
目的探讨固本消瘤加减方联合阿帕替尼治疗不可切除的非小细胞肺癌(NSCLC)患者的有效性及对免疫功能、肿瘤标志物的影响。方法前瞻性选取2018年5月至2022年10月河南中医药大学第一附属医院收治的87例不可切除NSCLC患者,按照就诊先后顺序,采用单双号法分为联合组(44例)、对照组(43例)。对照组接受阿帕替尼治疗,联合组在此基础上接受固本消瘤加减方。比较两组客观缓解率(ORR)、中医证候积分、免疫功能(CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+))、各血清指标[糖类抗原125(CA125)、癌胚抗原(CEA)、前梯度蛋白2(AGR2)、Pokemon]、毒副作用。结果联合组ORR(56.82%)高于对照组(32.56%)(P<0.05)。治疗3个疗程后,联合组咳嗽声低、痰多黏稠、神疲乏力、胸痛胸闷评分均低于对照组(P<0.05),CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)高于对照组(P<0.05),血清CA125、CEA、AGR2、Pokemon水平低于对照组(P<0.05)。治疗期间,联合组毒副反应发生率(22.73%)低于对照组(48.84%)(P<0.05)。结论固本消瘤加减方联合阿帕替尼治疗不可切除NSCLC的效果确切,能减轻免疫抑制及毒副作用,降低肿瘤标志物水平,调控AGR2、Pokemon表达。
Objective To investigate the efficacy of Guben Xiaoliu addition and reduction Formula combined with apatinib in the treatment of unresectable non-small cell lung cancer(NSCLC)and its effects on immune function and tumor markers.Methods A total of 87 patients with unresectable NSCLC admitted to the First Affiliated Hospital of Henan University of Traditional Chinese Medicine from May 2018 to October 2022 were prospectively selected and divided into combination group(44 cases)and control group(43 cases)according to the order of treatment by odd-even number method.The control group was given apatinib,and the combination group was given Guben Xiaoliu addition and reduction Formula on this basis.Objective response rate(ORR),traditional Chinese medicine(TCM)syndrome score,immune function(CD3^(+),CD4^(+),CD4^(+)/CD8^(+)),serum indexes[carbohydrate antigen 125(CA125),carcinoembryonic antigen(CEA),anterior gradient-2(AGR2),Pokemon],toxicity and side effects of the two groups were compared.Results The ORR of the combination group(56.82%)was higher than that(32.56%)of the control group(P<0.05).After 3 courses of treatment,the scores of cough,phlegm,fatigue,chest pain and chest tightness in the combined group were lower than those in the control group(P<0.05),CD3^(+),CD4^(+),CD4^(+)/CD8^(+)in the combination group were higher than those in the control group(P<0.05),the levels of serum CA125,CEA,AGR2 and Pokemon in the combination group were lower than those in the control group(P<0.05).During treatment,the incidence of toxic and side effects in the combination group(22.73%)was lower than that(48.84%)in the control group(P<0.05).Conclusion Guben Xiaoliu addition and reduction Formula combined with apatinib is effective in the treatment of unresectable NSCLC.It can reduce immunosuppression and toxic side effects,reduce the level of tumor markers,and regulate the expression of AGR2 and Pokemon.
作者
张俊红
ZHANG Junhong(Respiratory Department,the First Affiliated Hospital of Henan University of Traditional Chinese Medicine,Zhengzhou 450000,China)
出处
《河南医学研究》
CAS
2023年第10期1861-1865,共5页
Henan Medical Research
关键词
固本消瘤加减方
阿帕替尼
非小细胞肺癌
免疫功能
Guben Xiaoliu addition and reduction Formula
apatinib
non-small cell lung cancer
immune function
